Gland Pharma soars 13% on better than expected Q2 performance

Quick Summary:

Despite increased EBITDA loss at Cenexi, the overall consolidated EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.

With two years of earnings decline in FY23/FY24, Motilal Oswal Financial Services (MOFSL) believes the earnings are largely at trough and expected to witness revival over FY25-27.

Gland Pharma’s Q2FY25 revenue grew 2.4 per cent YoY to Rs 1,406 crore.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaBelgiumUnited States

Topics: Q2 result Q2 result today Cenexi MOFSL Gland Pharma q2 result Gland Pharma Gland Pharma share price Gland Pharma stock price Motilal Oswal Financial Services

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-05 @ 11:58:00 (8 hours ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 506 words

Reading Time: 3 minutes read

Sentences: 18 lines

Sentence Length: 29 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 23424616

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 279 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 2 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions